Legal & General Group
ADPT icon

Legal & General Group’s Adaptive Biotechnologies ADPT Stock Holding History

Legal & General Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.62M Buy
355,336
+30,731
+9% +$471K ﹤0.01% 1337
2026
Q1 		$4.51M Sell
324,605
-37,776
-10% -$602K ﹤0.01% 1557
2025
Q4 		$5.89M Buy
362,381
+116,454
+47% +$1.9M ﹤0.01% 1475
2025
Q3 		$3.68M Sell
245,927
-3,193
-1% -$38.9K ﹤0.01% 1727
2025
Q2 		$2.9M Buy
249,120
+43,927
+21% +$399K ﹤0.01% 1812
2025
Q1 		$1.52M Buy
205,193
+96,563
+89% +$742K ﹤0.01% 2021
2024
Q4 		$651K Buy
108,630
+97,798
+903% +$539K ﹤0.01% 2372
2024
Q3 		$55.5K Buy
10,832
+1,011
+10% +$4.41K ﹤0.01% 2780
2024
Q2 		$35.6K Sell
9,821
-93,095
-90% -$295K ﹤0.01% 2844
2024
Q1 		$330K Buy
102,916
+4,819
+5% +$18.6K ﹤0.01% 2580
2023
Q4 		$481K Sell
98,097
-340
-0.3% -$1.55K ﹤0.01% 2469
2023
Q3 		$536K Sell
98,437
-698
-0.7% -$4.62K ﹤0.01% 2406
2023
Q2 		$665K Buy
99,135
+3,474
+4% +$25.8K ﹤0.01% 2362
2023
Q1 		$845K Buy
95,661
+1,353
+1% +$11.9K ﹤0.01% 2194
2022
Q4 		$721K Buy
94,308
+1,569
+2% +$12.2K ﹤0.01% 2241
2022
Q3 		$660K Sell
92,739
-25,225
-21% -$238K ﹤0.01% 2268
2022
Q2 		$954K Buy
117,964
+27,325
+30% +$240K ﹤0.01% 2179
2022
Q1 		$1.26M Buy
90,639
+1,757
+2% +$27.6K ﹤0.01% 2157
2021
Q4 		$2.49M Buy
88,882
+418
+0.5% +$12.8K ﹤0.01% 1921
2021
Q3 		$3.01M Buy
88,464
+15,773
+22% +$570K ﹤0.01% 1812
2021
Q2 		$2.97M Buy
72,691
+15,960
+28% +$620K ﹤0.01% 1798
2021
Q1 		$2.28M Buy
56,731
+1,073
+2% +$58.1K ﹤0.01% 1925
2020
Q4 		$3.29M Sell
55,658
-9,669
-15% -$499K ﹤0.01% 1681
2020
Q3 		$3.18M Buy
65,327
+31,731
+94% +$1.33M ﹤0.01% 1563
2020
Q2 		$1.63M Buy
33,596
+12,354
+58% +$450K ﹤0.01% 1809
2020
Q1 		$589K Buy
21,242
+19,730
+1,305% +$550K ﹤0.01% 2024
2019
Q4 		$45K Buy
1,512
+656
+77% +$18.8K ﹤0.01% 2849
2019
Q3 		$26K Buy
+856
New +$34.9K ﹤0.01% 3029

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Legal & General Group's ADPT Position: Q2 2026 in Review

Legal & General Group increased its Adaptive Biotechnologies (ADPT) stake by 9.5% in Q2 2026, buying an estimated $471K and bringing the position to 355,336 shares worth $7.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1337.

Legal & General Group first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Legal & General Group held 355,336 shares of Adaptive Biotechnologies worth $7.62M as of Q2 2026.
  • Legal & General Group bought 30,731 Adaptive Biotechnologies shares in Q2 2026, an estimated $471K.
  • Adaptive Biotechnologies made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1337 holding.
  • Legal & General Group first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.